Aurobindo Pharma opened at ₹1,706.90, in line with its previous close of ₹1,706.90. During today's session, the stock has traded between ₹1,665.50 and ₹1,706.90, with an average traded price of ₹1,677.69. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Aurobindo Pharma is now worth
₹ 23,081.00
giving a profit of
₹ 13,081.00 (130.81%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-22.30 (-1.31%)
Day High
₹1,706.90
Day Low
₹1,665.50
Day Open
₹1,706.90
Prev Close
₹1,706.90
Volume
9,53,166
Value Traded
₹159.91 Cr
1W Return
0.58%
1M Return
0.29%
3M Return
7.66%
6M Return
24.84%
1Y Return
49.04%
Market Cap (₹ Cr.)
96,928
PE Ratio
26.40
PB Ratio
2.59
Dividend Yield
0.23%
ROE
9.25%
ROCE
13.58%
Book Value (₹)
658.53
Face Value (₹)
1.00
EPS (TTM)
17.86
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.58%
6 Week
-
1 Month
0.29%
3 Month
7.66%
9 Month
43.63%
Aurobindo Pharma gets USFDA approval for Perampanel tablets
Received USFDA final approval for Perampanel Tablets in six strengths. Targeting a $67 million market based on IQVIA MAT data for Aug 2026. Launch scheduled for Q3FY27 at wholly owned subsidiary APL Healthcare. Total USFDA ANDA approvals now stand at 599, including 574 final approvals.
10 days agoAurobindo subsidiary completes US CRDMO acquisition for $15.247 million
Completed acquisition of A1 Biochem Labs LLC for $15.247 million. Adds 50+ client base and 800+ project experience to CRDMO platform. Integrates US research capabilities with existing API manufacturing operations.
11 days agoAcrotech launches AdQuey in US, enters dermatology market
Acrotech Biopharma launched AdQuey ointment in the United States. The subsidiary established a dedicated dermatology division. This move expands Aurobindo Pharma's product portfolio in the US market.
12 days agoAurobindo Pharma confirms ₹4.60 crore GST demand for FY21
Total disputed amount stands at ₹4.60 crore for FY21. Principal tax demand of ₹2.56 crore linked to excess ITC claims. Interest of ₹1.78 crore and penalty of ₹0.26 crore also confirmed. Company plans to appeal before the GST Appellate Tribunal.
14 days agoAurobindo Pharma to host JP Morgan analyst meet in Hyderabad
Aurobindo Pharma schedules investor meet for September 24, 2026. Session is part of JP Morgan Healthcare Trip in Hyderabad. Meeting runs from 2:30 pm to 3:30 pm in group format. No UPSI to be discussed during the interaction.
22 days agoAurobindo Pharma gets USFDA approval for Beclomethasone HFA aerosol
Aurobindo Pharma receives USFDA final approval for Beclomethasone HFA Inhalation Aerosol 40 mcg and 80 mcg on September 15, 2026. This is the company's first metered-dose inhaler (MDI) product, a generic equivalent of Teva's QVAR®. The product will be manufactured at the company's Raleigh, North Carolina facility owned by Aurolife Pharma LLC. The US market for the approved product is estimated at $301 million for the twelve months ended July 2026. Cumulative USFDA ANDA approvals for Aurobindo Pharma now stand at 596.
28 days ago| Contract | Days to Expiry | LTP | Change | Change % | Volume | OI | OI Chg % |
|---|---|---|---|---|---|---|---|
| AUROPHARMA OCT FUT | 15 | 1,695.20 | -11.50 | -0.67 | 9,88,900 | 1,28,59,000 | 0.65 |
| AUROPHARMA NOV FUT | 42 | 1,699.60 | -14.30 | -0.83 | 86,350 | 1,25,400 | 37.35 |
| AUROPHARMA DEC FUT | 78 | 1,713.20 | -9.80 | -0.57 | 25,850 | 32,450 | 145.83 |
| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% | |
| ₹351.00 | +1.34% | ₹57,202.26 | 134.86 | -0.69% |
An investment of ₹10,000 made 5 years ago in Aurobindo Pharma is now worth
₹ 23,081.00
giving a profit of
₹ 13,081.00 (130.81%)
Note: Past profits do not guarantee future returns.
